Tannin Phytocomplex Improves IBS-D Symptoms and Gut-Brain Markers: Prospective Pilot Study

Area of Science:

• Gastroenterology
• Nutritional Science
• Microbiome Research

Background:

• Diarrhea-predominant irritable bowel syndrome (IBS-D) involves complex gut-brain axis dysregulation, impaired gut barrier, and microbial imbalances.
• Current nutritional strategies for IBS-D are limited, highlighting the need for novel therapeutic approaches.
• Tannins, plant-derived polyphenols, show potential for barrier protection, microbiota modulation, and stress reduction.

Purpose of the Study:

• To evaluate the efficacy of tannin-based supplementation in adults with IBS-D.
• To assess the impact of tannin supplementation on gastrointestinal symptoms, psychological factors, and relevant biomarkers.
• To explore potential mechanisms of action, including effects on gut barrier integrity and microbial metabolism.

Main Methods:

• A prospective before-after pilot study involving 28 adults diagnosed with IBS-D.
• Participants received 480 mg/day of a tannin-based phytocomplex for 60 days.
• Outcomes measured included IBS Severity Scoring System (IBS-SSS), bowel habits, somatization, perceived stress, serum zonulin, fecal short-chain fatty acids (SCFAs), and hydrogen breath tests.

Main Results:

• Significant reductions in IBS-SSS scores (mean decrease of 70 points, p < 0.0001) and improvements in stool consistency were observed.
• Bowel movement frequency decreased, while somatization and perceived stress scores significantly declined (p ≤ 0.003).
• Biomarker analysis revealed decreased serum zonulin (p < 0.0001), increased fecal butyrate (p = 0.001), and decreased propionate (p = 0.017). Hydrogen breath tests normalized in all initially positive subjects.

Conclusions:

• Tannin-based phytocomplex supplementation appears to effectively improve both gastrointestinal and psychological symptoms in individuals with IBS-D.
• Observed biomarker changes suggest enhanced gut barrier function and a shift towards a healthier microbial metabolic profile.
• These promising results warrant larger, controlled clinical trials to confirm the therapeutic potential of tannins for IBS-D management.